Clonal Evolution

Chromosomal Instability

Properties1
tagsgenomic-alterations

5 min read

Chromosomal Instability

Definition

Chromosomal instability (CIN) is a type of genomic instability involving ongoing errors in chromosome segregation during mitosis, resulting in whole-chromosome or segmental aneuploidy. CIN can also arise from errors of DNA replication and repair (Turajlic et al., 2019). It is distinct from tumors that are clonally aneuploid due to a single missegregation event without ongoing instability — such tumors are homogeneously aneuploid, whereas CIN-driven tumors are heterogeneously (subclonally) aneuploid.

CIN is a defining feature of most solid cancers. As Gerstung et al. (2020) demonstrated, CIN and the copy number alterations it generates affect a greater proportion of the cancer genome than any other mutation type.

Dual Role: Adaptive and Deleterious

CIN has a paradoxical relationship with fitness:

Adaptive potential. CIN provides the raw material for hopeful-monsters — grossly altered clones that may carry multiple adaptive copy-number-alterations simultaneously. It enables rapid phenotypic exploration through large-scale karyotypic change (Turajlic et al., 2019).

Fitness cost. Excessive CIN is lethal. In a pan-cancer analysis of >2,000 samples, only moderate CIN (>25% and <75%) was associated with decreased survival; excessive CIN conferred improved prognosis, consistent with a fitness cost that negates the selective advantage of karyotypic heterogeneity (Turajlic et al., 2019). As Turajlic et al. note, “low levels of aneuploidy may be tumour protective but…the genome-destabilising effects of aneuploidy are tumour-promoting under certain growth conditions” (p. 406).

This creates selection for a “just-right” level of CIN — enough to generate adaptive diversity, but not so much that it causes cell-autonomous lethality.

Dynamic vs. static CIN. Jamal-Hanjani et al. (2017) introduced a critical distinction: ongoing dynamic CIN (measured by inter-region copy-number heterogeneity across multiregion samples) is prognostic, while accumulated static chromosomal disruption (measured by mean aberrant genome fraction in a single sample) is not. In TRACERx NSCLC (N = 100), mirrored subclonal allelic imbalance — when the maternal allele is gained/lost in one subclone and the paternal allele in another — was detected in 62% of 92 evaluable tumors (375 events), providing direct evidence of ongoing dynamic CIN producing parallel evolution of driver CNAs (CDK4, FOXA1, BCL11A). Mirrored subclonal allelic imbalance was significantly enriched in genome-doubled tumors (P = 0.004), establishing WGD as an early permissive event for subsequent CIN-driven diversification. This dynamic/static distinction has clinical implications: a single-biopsy measure of aneuploidy may miss the ongoing process that actually drives poor outcome.

CIN and Metastasis

CIN is strongly associated with metastatic competence. In TRACERx Renal, the critical difference between metastasis-competent and non-metastasizing clones was the degree of aneuploidy and chromosome complexity. Specific CNAs — loss of 9p and loss of 14q — were enriched in metastasizing clones, while no evidence of selection for small-scale SNV mutations was found (Turajlic et al., 2019).

CIN and Clinical Outcomes

In TRACERx Lung, CIN conferred an increased risk of recurrence and death independently of known predictive markers (Jamal-Hanjani et al., 2017, cited in Turajlic et al., 2019). CIN is also linked to resistance to chemotherapy and to CTLA4 and PD1 immune checkpoint inhibitors (Turajlic et al., 2019).

CIN and Immune Evasion

CIN has a dual relationship with the immune system — it can enable escape, but at high levels it may increase visibility.

Immune escape. CIN can lead to subclonal loss of heterozygosity in HLA genes, facilitating immune escape. In NSCLC, pervasive evidence of positive selection was found for HLA LOH events, which allow tumors to accumulate subclonal neo-antigens without triggering immune clearance (McGranahan et al., 2017, cited in Turajlic et al., 2019). Additionally, loss of chromosomal segments containing neoantigen-coding mutations eliminates the antigens that would otherwise mark the clone for immune clearance (copy-number-alteration).

Immune visibility at high CIN. Excessive chromosomal instability may increase immune visibility through a mechanism complementary to the cell-autonomous fitness cost: more chromosomal rearrangements → more frameshift peptides and aberrant proteins → higher neo-antigen burden presented on MHC-I → better immune recognition. This neoantigen-visibility mechanism may synergize with the fitness-cost mechanism (see Dual Role) to improve outcomes at the high-CIN extreme. However, tumors under immune pressure may counter-adapt through HLA LOH — the net effect depends on whether CIN-driven neoantigen generation outpaces immune evasion.

CIN vs. ITH: Inverted Outcome Curves

The CIN-outcome relationship and the ITH-outcome relationship (intratumor-heterogeneity §5) run in opposite directions:

PhenomenonNatureLowModerateHighCurve
CIN → outcomeProcess rateBetterWorseBetterInverted-U (∩)
ITH → outcome (compression-entrenchment)StateWorseBetterWorseU (∪)

CIN is a process — the ongoing rate of chromosome segregation errors generating new CNA. ITH is a state — the existing diversity at a snapshot in time. Moderate CIN produces worse outcome because it maximizes the rate of adaptive CNA generation; moderate ITH is predicted to produce better outcome (per the compression-entrenchment hypothesis) because it represents a transitional, un-entrenched state with active clonal competition. The two curves are not contradictory — they operate at different levels (process vs. state) — but they interact: CIN is what generates the CNA dimension of ITH. At high CIN, the process collapses under its own fitness cost regardless of the ITH it generates.

This distinction matters for clinical interpretation: a tumor with high ITH from past CIN (now quiescent) is biologically different from a tumor with moderate ITH from ongoing active CIN. The former is a legacy state; the latter is an active generator of future diversity. Current bulk-sequencing metrics do not cleanly separate these scenarios.

Graph View

Backlinks